Until recently, itch pathophysiology was poorly understood and treatments were poorly effective in relieving itch. Current progress in our knowledge of the itch processing, the numerous mediators and receptors involved has led to a large variety of possible therapeutic pathways. Currently, inhibitors of IL-31, IL-4/13, NK1 receptors, opioids and cannabinoids, JAK, PDE4 or TRP are the main compounds involved in clinical trials. However, many new targets, such as Mas-related GPCRs and unexpected new pathways need to be also explored. Read full article

autophagy deficiency in myeloid cells "Background Eosinophilic inflammation is a hallmark of refractory chronic

March 2022 Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B portfolio of CB1 inverse agonists, announced today the dosing of the first participant with metabolic syndrome pharmacokinetics and safety profile of Inversago’s lead molecule, INV-202, on a targeted population with metabolic syndrome

October 9, 2023 Abstract "There is increasing evidence for an autoimmune aetiology in post-infectious Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Due to the urgency of finding therapies for post-COVID-Syndrome (PCS), we report here the interim results Encephalomyelitis/Chronic Fatigue Syndrome , SF-36 , autoantibodies , immunoadsorption , long COVID , physical function , post-COVID syndrome Source Contribute to the GPCR News Coming soon Become a Contributor

However, Gpr141 deficiency exacerbated disease conditions of experimental autoimmune encephalomyelitis Gr1- monocytes, CD11c+ dendritic cells, and CD4+ T cell infiltration into the experimental autoimmune encephalomyelitis-induced dendritic cells and that targeting GPR141 may be a possible therapeutic intervention for modulating chronic Tags G protein–coupled receptor 141 , autoimmune disease , dendritic cells , experimental autoimmune encephalomyelitis

autonomic nervous system receptors Published date September 7, 2023 Abstract "Background: The Long-COVID syndrome CERAD Trail Marking A and B (R ≤ -0.26, p ≤ 0.043), while CHRM3 correlated positively with Chadler Fatigue correlates to intensity of neurological disorders including psychomotor speed, visual search, attention, and fatigue